Dasatinib-related pleural effusion and lymphocytosis rates are different between adult and pediatric patients with Philadelphia chromosome-positive leukemias: are age and comorbidities only to blame?

References

• Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691–709.
   PubMed Web of Science ®Google Scholar
• McCafferty EH, Dhillon S, Deeks ED. Dasatinib: a review in pediatric chronic myeloid leukemia. Paediatr Drugs. 2018;20(6):593–600.
   PubMed Web of Science ®Google Scholar
• Hijiya N, Schultz KR, Metzler M, et al. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood. 2016;127(4):392–399.
   PubMed Web of Science ®Google Scholar
• Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008;26(19):3204–3212.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260–2270 .
   PubMed Web of Science ®Google Scholar
• Foà R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118(25):6521–6528.
   PubMed Web of Science ®Google Scholar
• Keskin D, Sadri S, Eskazan AE. Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations. Drug Des Devel Ther. 2016;10:3355–3361.
   PubMed Web of Science ®Google Scholar
• Eskazan AE, Eyice D, Kurt EA, et al. Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion. Leuk Res. 2014;38(7):781–787.
   PubMed Web of Science ®Google Scholar
• Yüzbaşıoğlu MB, Eşkazan AE. Bosutinib - related pleural effusion in patients with chronic myeloid leukemia. Expert Opin Drug Saf. 2021;20(4):379–381.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Jimenez CA, Mauro MJ, et al. Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management. Clin Lymphoma Myeloma Leuk. 2017;17(2):78–82.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–2340.
   PubMed Web of Science ®Google Scholar
• Shah NP, Rousselot P, Schiffer C, et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016;91(9):869–874.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Kantarjian H, O’brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25(25):3908–3914.
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Punnialingam S, Milojkovic D, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol. 2008;141(5):745–747.
   PubMed Web of Science ®Google Scholar
• Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23(8):1398–1405.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Laneuville P, Rousselot P, et al. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica. 2019;104(1):93–101.
   PubMed Web of Science ®Google Scholar
• Porkka K, Khoury HJ, Paquette RL, et al. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010;116(2):377–386.
   PubMed Web of Science ®Google Scholar
• Latagliata R, Breccia M, Fava C, et al. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. Hematol Oncol. 2013;31(2):103–109.
   PubMed Web of Science ®Google Scholar
• Ernst T, Busch M, Rinke J, et al. Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia. Leukemia. 2018;32(9):2046–2049.
   PubMed Web of Science ®Google Scholar
• Zwaan CM, Rizzari C, Mechinaud F, et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the innovative therapies for children with cancer consortium. J Clin Oncol. 2013;31(19):2460–2468.
   PubMed Web of Science ®Google Scholar
• Gore L, Kearns PR, de Martino ML, et al. Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: results from a phase II trial. J Clin Oncol. 2018;36(13):1330–1338.
   PubMed Web of Science ®Google Scholar
• Slayton WB, Schultz KR, Kairalla JA, et al. Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of children’s oncology group trial AALL0622. J Clin Oncol. 2018;36(22):2306–2314.
   PubMed Web of Science ®Google Scholar
• Phan C, Jutant EM, Tu L, et al. Dasatinib increases endothelial permeability leading to pleural effusion. Eur Respir J. 2018;51(1):1701096.
   PubMed Web of Science ®Google Scholar
• Kelly K, Swords R, Mahalingam D, et al. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Target Oncol. 2009;4(2):99–105.
   PubMed Web of Science ®Google Scholar
• Qiu ZY, Xu W, Li JY. Large granular lymphocytosis during dasatinib therapy. Cancer Biol Ther. 2014;15(3):247–255.
   PubMed Web of Science ®Google Scholar
• Ishiyama K, Kitawaki T, Sugimoto N, et al. Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib. Leukemia. 2017;31(1):203–212.
   PubMed Web of Science ®Google Scholar
• Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004;22(5):935–942.
   PubMed Web of Science ®Google Scholar
• van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009;35(8):692–706.
   PubMed Web of Science ®Google Scholar
• Naqvi K, Jabbour E, Skinner J, et al. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020;126(1):67–75.
   PubMed Web of Science ®Google Scholar
• Rousselot P, Mollica L, Guilhot J, et al. Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. Br J Haematol. 2021;194(2):393–402.
   PubMed Web of Science ®Google Scholar
• Wang X, Roy A, Hochhaus A, et al. Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a phase III study. Clin Pharmacol. 2013;5:85–97.
   PubMedGoogle Scholar
• Brandenberger C, Mühlfeld C. Mechanisms of lung aging. Cell Tissue Res. 2017;367(3):469–480.
   PubMed Web of Science ®Google Scholar
• Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008;22(10):1276–1312.
   PubMed Web of Science ®Google Scholar
• Mustjoki S, Auvinen K, Kreutzman A, et al. Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia. 2013;27(4):914–924.
   PubMed Web of Science ®Google Scholar
• Tarr T, Dérfalvi B, Győri N, et al. Similarities and differences between pediatric and adult patients with systemic lupus erythematosus. Lupus. 2015;24(8):796–803.
   PubMed Web of Science ®Google Scholar
• Cypess AM, Kahn CR. The role and importance of brown adipose tissue in energy homeostasis. Curr Opin Pediatr. 2010;22(4):478–484.
   PubMed Web of Science ®Google Scholar